NovoCure director granted RSUs and stock options
NovoCure Ltd director Martin J. Madden received new equity awards as part of his compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
NovoCure Ltd director Martin J. Madden received new equity awards as part of his compensation. He was granted 11,610 ordinary shares in the form of restricted stock units, which are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders.
He was also granted stock options covering 16,999 ordinary shares at an exercise price of $16.15 per share, expiring in 2036. These options will fully vest and become exercisable on the same schedule as the restricted stock units. Following the share grant, Madden directly holds 30,284 ordinary shares.
Insider Trade Summary
Grant/Award: 28,609 shares
Grant/Award
2 txns
Insider
Madden Martin J.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 16,999 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares | 11,610 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 16,999 contracts (Direct);
Ordinary Shares — 30,284 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
- F2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Key Figures
Restricted stock units granted: 11,610 shares
Stock options granted: 16,999 options
Option exercise price: $16.15 per share
+3 more
6 metrics
Restricted stock units granted
11,610 shares
RSUs scheduled to vest by 2027 meeting
Stock options granted
16,999 options
Right to buy NovoCure ordinary shares
Option exercise price
$16.15 per share
Exercise price for 16,999 options
Option expiration
2036-06-03
Expiration date for granted options
Shares held after grant
30,284 shares
Direct NovoCure ordinary share ownership
RSU vesting trigger
2027 AGM-related date
Earlier of 1-year anniversary or pre-2027 AGM
Key Terms
restricted stock units, Stock Option (Right to Buy), vest, annual general meeting of shareholders, +1 more
5 terms
restricted stock units financial
"Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 16.1500 per share"
vest financial
"restricted stock units that are scheduled to vest 100% on the earlier of the following dates"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"Options to buy ordinary shares will fully vest and become exercisable with an exercise price of 16.1500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NovoCure (NVCR) director Martin J. Madden receive in this Form 4 filing?
Director Martin J. Madden received equity-based compensation awards from NovoCure. He was granted 11,610 restricted stock units and stock options for 16,999 ordinary shares, reflecting routine director compensation rather than open-market share purchases or sales.
How many NovoCure (NVCR) restricted stock units were granted to Martin J. Madden?
Martin J. Madden was granted 11,610 restricted stock units in NovoCure ordinary shares. These units are scheduled to vest 100% on the first anniversary of the grant date or the day immediately before NovoCure's 2027 annual general meeting of shareholders, whichever occurs earlier.
What are the key terms of Martin J. Madden’s NovoCure (NVCR) stock options?
Madden received options to buy 16,999 NovoCure ordinary shares at an exercise price of $16.15 per share. The options fully vest on the first anniversary of the grant date or the day immediately before the 2027 annual general meeting, and expire in 2036.
When do Martin J. Madden’s NovoCure (NVCR) restricted stock units vest?
His 11,610 restricted stock units vest 100% on the earlier of two dates: the first anniversary of the grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders, creating a single cliff-vesting event for the entire award.
Are Martin J. Madden’s NovoCure (NVCR) transactions open-market buys or sales?
The transactions are not open-market trades. They represent compensation-related grants of restricted stock units and stock options, with no purchase price for the awards and no reported market sales or purchases of NovoCure shares in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
